Janssen
Carvykti (ciltacabtagene autoleucel) is a BCMA CAR-T for relapsed/refractory multiple myeloma, advanced through the LEGEND-2 programme and a growing real-world evidence base.
- Country
- United States
Commercial
BCMA CAR-T (Carvykti)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bispecific & multispecific antibodies | therapeutics-platforms | Low | → |
| CAR-T cell therapy | therapeutics-platforms | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.